 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12...234567891011121314» |
- | Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
Trial completion: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 14, 2018
P1, N=80, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: Additional Insulin for Fat and Protein in Children With Diabetes Study (clinicaltrials.gov) - Aug 31, 2018
P4, N=40, Recruiting, Sponsor: Oxford University Hospitals NHS Trust
Recruiting --> Completed Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: Evaluation of Fiasp (clinicaltrials.gov) - Aug 24, 2018
P4, N=20, Recruiting, Sponsor: Stanford University
Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- Victoza (liraglutide) / Novo Nordisk
Phase classification: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting (clinicaltrials.gov) - Aug 21, 2018
P2, N=18, Completed, Sponsor: Albert Einstein College of Medicine, Inc.
Not yet recruiting --> Recruiting Phase classification: P1 --> P2
- | Trial completion, Trial completion date: Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (clinicaltrials.gov) - Aug 17, 2018
P4, N=181, Completed, Sponsor: Mackay Memorial Hospital
Phase classification: P1 --> P2 Recruiting --> Completed | Trial completion date: May 2016 --> Aug 2016
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Metastases: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) - Aug 1, 2018
P=N/A, N=176, Suspended, Sponsor: Imperial College London
Recruiting --> Completed | Trial completion date: May 2016 --> Aug 2016 Trial completion date: Jul 2018 --> Aug 2019
- | HinsBet (human insulin) / Adocia, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial initiation date: Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas (clinicaltrials.gov) - Aug 1, 2018
P=N/A, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Jul 2018 --> Aug 2019 Initiation date: Sep 2018 --> Dec 2018
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Enrollment change: A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 12, 2018
P1, N=46, Completed, Sponsor: Novo Nordisk A/S
Initiation date: Sep 2018 --> Dec 2018 Recruiting --> Completed | N=66 --> 46
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 9, 2018
P3, N=1072, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=66 --> 46 Recruiting --> Active, not recruiting
- || SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
Enrollment change: Safety Assessment of SAR341402 and NovoLog (clinicaltrials.gov) - Jul 6, 2018
P1, N=46, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting N=30 --> 46
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New P2/3 trial: The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) - Jun 20, 2018
P2/3, N=88, Recruiting, Sponsor: Massachusetts General Hospital
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P4 trial: Evaluation of Fiasp (clinicaltrials.gov) - Jun 13, 2018
P4, N=20, Not yet recruiting, Sponsor: Stanford University
- | New P4 trial: Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia (clinicaltrials.gov) - Apr 26, 2018
P4, N=50, Recruiting, Sponsor: Northwestern University
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: onset (clinicaltrials.gov) - Apr 5, 2018
P3, N=834, Completed, Sponsor: Novo Nordisk A/S
N=30 --> 46 Active, not recruiting --> Completed
- | Tresiba (insulin degludec) / Novo Nordisk
Trial completion date, Trial primary completion date: HypoDeg: Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (clinicaltrials.gov) - Apr 4, 2018
P4, N=149, Active, not recruiting, Sponsor: Nordsjaellands Hospital
Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Apr 2019 | Trial primary completion date: Dec 2017 --> Apr 2019
- || Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion date, Trial primary completion date: Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) (clinicaltrials.gov) - Apr 4, 2018
P4, N=150, Recruiting, Sponsor: Sanofi
Trial completion date: Dec 2017 --> Apr 2019 | Trial primary completion date: Dec 2017 --> Apr 2019 Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019
- ||| Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
Enrollment open, Trial completion date, Trial primary completion date: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 29, 2018
P1, N=86, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019 Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jun 2018
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial suspension, Metastases: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) - Mar 8, 2018
P=N/A, N=176, Suspended, Sponsor: Imperial College London
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jun 2018 Trial completion date: Jul 2016 --> Jul 2018 | Recruiting --> Suspended
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Mar 3, 2018
P3, N=803, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Jul 2016 --> Jul 2018 | Recruiting --> Suspended Trial primary completion date: Feb 2018 --> Feb 2018
- || Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion date, Trial primary completion date: SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) - Mar 3, 2018
P4, N=400, Recruiting, Sponsor: Sanofi
Trial primary completion date: Feb 2018 --> Feb 2018 Trial completion date: Sep 2019 --> Nov 2019 | Trial primary completion date: Sep 2019 --> Nov 2019
- ||| Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
New P1 trial: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 27, 2018
P1, N=86, Not yet recruiting, Sponsor: Eli Lilly and Company
- | SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
New P1 trial: Safety Assessment of SAR341402 and NovoLog (clinicaltrials.gov) - Feb 19, 2018
P1, N=30, Not yet recruiting, Sponsor: Sanofi
- | HinsBet (human insulin) / Adocia, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial initiation date: Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Sep 2019 --> Nov 2019 | Trial primary completion date: Sep 2019 --> Nov 2019 Initiation date: Jan 2018 --> Apr 2018
- | Byetta (exenatide) / AstraZeneca
Trial completion date, Trial primary completion date: New Onset Type 1 Diabetes: Role of Exenatide (clinicaltrials.gov) - Feb 7, 2018
P4, N=20, Recruiting, Sponsor: Albert Einstein College of Medicine, Inc.
Initiation date: Jan 2018 --> Apr 2018 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Jun 2019
- |||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Enrollment open, Trial initiation date: SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) - Feb 6, 2018
P4, N=400, Recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Jan 2018
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Novolin R (recombinant human insulin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: NASO-PET: Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=10, Completed, Sponsor: Turku University Hospital
Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Jan 2018 Recruiting --> Completed
- |||| SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
Trial primary completion date: GEMELLI 1: Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Jan 24, 2018
P3, N=580, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Trial primary completion date: Jan 2019 --> Jul 2018
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 23, 2018
P1, N=66, Recruiting, Sponsor: Novo Nordisk A/S
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset (clinicaltrials.gov) - Jan 19, 2018
P3, N=803, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2019 --> Jul 2018 Recruiting --> Active, not recruiting
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Trial primary completion date, Surgery: Sitagliptin in Non-Diabetic Patients Undergoing General Surgery (clinicaltrials.gov) - Jan 16, 2018
P4, N=80, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Apr 2017
- |||| Tresiba (insulin degludec) / Novo Nordisk
Enrollment open, Surgery: Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 10, 2018
P4, N=180, Recruiting, Sponsor: Emory University
Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Apr 2017 Not yet recruiting --> Recruiting
- | Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 4, 2018
P4, N=250, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Dec 12, 2017
P1, N=43, Completed, Sponsor: Adocia
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Dec 6, 2017
P3, N=1108, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Trial primary completion date: Aug 2017 --> May 2017
- | Januvia (sitagliptin) / Merck (MSD)
Trial primary completion date, Surgery: SITA-CABGDM: Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (clinicaltrials.gov) - Dec 5, 2017
P4, N=200, Recruiting, Sponsor: Emory University
Trial primary completion date: Aug 2017 --> May 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- ||||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
New P4 trial: SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) - Dec 2, 2017
P4, N=400, Not yet recruiting, Sponsor: Sanofi
- ||||| Tresiba (insulin degludec) / Novo Nordisk
New P4 trial, Surgery: Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 8, 2017
P4, N=180, Not yet recruiting, Sponsor: Emory University
- | New P4 trial: Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (clinicaltrials.gov) - Nov 1, 2017
P4, N=300, Recruiting, Sponsor: Fundaci
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Sep 21, 2017
P3, N=1072, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- |||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Apidra (insulin glulisine) / Sanofi
Enrollment open: Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) (clinicaltrials.gov) - Sep 8, 2017
P4, N=150, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: onset (clinicaltrials.gov) - Sep 6, 2017
P3, N=1108, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Aug 31, 2017
P3, N=1072, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | HinsBet (human insulin) / Adocia, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New trial: Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas (clinicaltrials.gov) - Aug 24, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Apidra (insulin glulisine) / Sanofi
New P4 trial: Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) (clinicaltrials.gov) - Aug 23, 2017
P4, N=150, Not yet recruiting, Sponsor: Sanofi
- |||||| SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
Enrollment open: GEMELLI 1: Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Aug 3, 2017
P3, N=500, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jul 27, 2017
P3, N=472, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk, Prandilin (insulin lispro biosimilar) / Gan & Lee Pharma, Sandoz
New P4 trial: Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes (clinicaltrials.gov) - Jul 20, 2017
P4, N=110, Completed, Sponsor: Nanjing First Hospital, Nanjing Medical University
- |||||||||| SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
New P3 trial: GEMELLI 1: Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Jul 7, 2017
P3, N=500, Not yet recruiting, Sponsor: Sanofi
- | SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
New P1 trial: A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 29, 2017
P1, N=30, Completed, Sponsor: Sanofi
- | Apidra (insulin glulisine) / Sanofi
Trial completion: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 12, 2017
P1, N=44, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Completed